|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Plasma matrix metal- loproteinase-9,tissue inhibitor of metalloproteinase-2,and CD40 ligand levels in patients with stable coronary artery dis- ease显示文摘 | Tayebjee M H Lip G Y Tan K T | 2005 | Am J Cardiol2005，96，3： | 1 |
| 2 | Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of metalloproteinases(MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases(TIMP)-1 and -2显示文摘 | Tayebjee MH Lip GY Blann AD | 2005 | Thrombosis Res2005，115，3： | 1 |
| 3 | Characterization of fractionated atrial electrograms critical for maintenance of atrial fibrillation:a randomized,controlled trial of ablation strategies (the CFAE AF Trial)显示文摘 | Hunter R J Diab I Tayebjee M | | 0，，5： | 1 |
| 4 | Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 in type 2 diabetes : effect of 1 year's cardiovascular risk reduction therapy 显示文摘 | Tayebjee MH Lira HS Macfadyen RJ | 2004 | Diabetes Care2004，27，8： | 1 |
| 5 | Right atrialflutter isthmus ablation is feasible and results in acute clinicalimprovement in patients with persistent atrial flutter and severepulmonary arterial hypertension显示文摘 | Showkathali R Tayebjee MH Gibbs SR | 2011 | Int J Cardiol2011，1492，： | 1 |
| 6 | Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)显示文摘 | TAYEBJEE M H NADAR S BLANN A D | 2004 | AmJ Hypertens2004，17，： | 1 |
| 7 | Is soluble CD40 ligand a mediator of angiogenesis in patients with coronary artery disease 显示文摘 | Lim HS Tayebjee MH Tan KT | 2008 | ? Thromb Res2008，122，3： | 1 |
| 8 | Circulating endothelial cells,von Willebrand factor,intedeukin-6,and prognosis in patients with acute coronary syndromes显示文摘 | Lee KW Lip GY Tayebjee M | 2005 | Blood2005，105，2： | 1 |
| 9 | Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)显示文摘 | Tayebjee M H Nadar S Blann A D | 2004 | Am J Hypertens2004，17，9： | 1 |
| 10 | Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and-2 in type 2 diabetes : effect of 1 year's cardiovascular risk reduction therapy 显示文摘 | Tayebjee MH Lira HS MacFadyen RJ | 2004 | Diabetes Care2004，27，： | 1 |
| 11 | Matrix metalloproteinase- 9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment : a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) 显示文摘 | Tayebjee MH Nadar S Blann AD | 2004 | Am J Hypertens2004，17，9： | 1 |
| 12 | Genetics of congenital and drug-induced long QT syndromes: current evidence and future research perspectives显示文摘 | Saagar Mahida Andrew J. Hogarth Campbell Cowan Muzahir H. Tayebjee Lee N. Graham Christopher B. Pepper | 2013 | Journal of Interventional Cardiac Electrophysiology2013，，1： | 1 |
| 13 | Circulating Matrix metalloproteinases-9 and tissue inhibitors of metalloproteinases-1 and-2 levels in gestational hypertension 显示文摘 | Tayebjee MH Karalis I Nadar SK | 2005 | Am J Hyper2005，18，3： | 1 |
| 14 | MacFadyen RJ Lip GY Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 and -2 levels in gestational hypertension显示文摘 | Tayebjee MH Karalis I Nadar SK | 2005 | Am J Hypertens2005，18，3： | 1 |
| 15 | Collateralization and the response to obstruction of epicardial coronary arteries显示文摘 | Tayebjee M H Lip G Y MacFadyen R J | 2004 | QJM2004，97，5： | 1 |
| 16 | Matrix metallopro teinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment:a sub-study of the Anglo-Scandinavian cardiac outcomes trial (ASCOT)显示文摘 | Tayebjee MH Nadar S Blann AD | 2004 | Am J Hypertens2004，17，9： | 1 |
| 17 | Extracellularmatrix biology: a new frontier in linking the pathology and therapy of hypentension 显示文摘 | TAYEBJEE M H MACFADYEN R J LIP G Y | 2003 | J Hypertens2003，21，12： | 1 |
| 18 | Relation of platelet activation to coronary angiographic severity and collateralization 显示文摘 | Tan KT Tayebjee MH Macfadyen RJ | 2005 | Am J Cardiol2005，96，2： | 1 |
| 19 | Cirolating endothelial cells,von Willebrand factor,interleukin-6,and prognosis in patients with acute coronary syndromes显示文摘 | Lee KW Lip GY Tayebjee M | 2005 | Blood2005，105，2： | 1 |
| 20 | Matrix metallo- proteinases in coronary artery disease: clinical and ther- apeutic implications and pathological significance显示文摘 | Tayebjee MH Lip H Gregory Y | 2005 | Cur- rent medicinal chemistry2005，12，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员